Singapore-based healthcare firm expands into stem cell therapies and longevity as demand for proactive aging solutions grows across Asia.
Singapore-based health technology company EUDA Health Holdings Limited has taken a major step in its longevity strategy with the launch of a comprehensive stem cell therapy platform and the opening of its first longevity clinic in Shenzhen, China.
The move marks a shift from planning to execution as the company positions itself at the intersection of regenerative medicine, preventive healthcare, and aging innovation.
For EUDA, this is not simply about opening a new clinic. It is about building an end-to-end system that moves from research and cell production to real-world patient care, at a time when aging populations across Asia are reshaping healthcare priorities.
The Shenzhen launch builds on EUDA’s earlier acquisition of distribution rights for T-cell immunotherapies developed by Shenzhen Inno Immune Company, as well as its announced intention to acquire Singapore-based biotechnology firm GO POSB Organoids Pte.
Together, these moves signal EUDA’s intent to go beyond non-invasive care and into advanced but accessible regenerative therapies. The company is integrating production, clinical delivery and long-term health planning into a single ecosystem.
At the center of this expansion is the upgrade of Shenzhen Inno’s existing cGMP facility, which EUDA is transforming into a production and innovation hub for stem cell and immune-based treatments.
This facility will be responsible for preparing stem cells and immune cells for use in clinical settings. The upgraded site also brings together technologies from GO POSB and two Japanese partners, including Japan Early Light Medical Corporation.
One of the key platforms being introduced is induced pluripotent stem cell (iPSC) technology. This process allows scientists to take ordinary blood cells and reprogram them into stem cells that can later develop into different cell types.
While the science is complex, the promise is straightforward: more flexible, personalized approaches to repairing and supporting the body as it ages.
The facility will also support work in immune health, skin health and healthy aging – areas where demand is rising as patients look for preventive, long-term solutions rather than reactive treatment.
Running alongside the production upgrade is the launch of EUDA’s Shenzhen longevity clinic, established in partnership with KB International Ltd. The clinic is designed to be among the first in the region to introduce Japanese longevity healthcare technologies to patients in China comprehensively.
The clinic will offer advanced stem cell and T-cell immunotherapies produced locally, alongside personalized, AI-guided life cycle management. This means patients are not just treated for current conditions, but supported with longer-term health planning based on their individual risk factors and goals.
What sets the clinic apart is its integrated approach. Services combine Eastern and Western medical practices with functional medicine, reflecting how many patients in Asia already view health and aging not as a single intervention but as a continuous process.
The clinic will also draw on partnerships with longevity institutions and hospitals in Japan, the United States and Singapore, giving it access to global expertise while remaining rooted in the local healthcare landscape.
EUDA Chief Executive Officer Alfred Lim described the launch as a turning point for the company.
“This is a defining moment in EUDA’s evolution,” Lim said. “By combining an iPSC platform, expanding stem cell and T-cell therapies, the new upgraded GMP facility’s production capacity, and a fully integrated longevity clinic, we are building a comprehensive, end-to-end regenerative ecosystem.”
He added that partnerships with Shenzhen Inno, GO POSB and Japanese clinical experts place EUDA “at the frontier of healthcare” as the longevity sector continues to grow.
Demographics is driving that growth. Across Asia, populations are aging rapidly, and traditional healthcare systems, largely designed to treat illness after it appears, are struggling to adapt. Companies like EUDA are betting that the future lies in prevention, early intervention and personalized care.
EUDA Health Holdings Limited focuses on Singapore, Malaysia and China. Its long-term ambition is to become a market leader in non-invasive and preventive healthcare, with longevity at the core of its strategy.
As more than 30% of the region’s population moves into older age brackets, EUDA sees an opportunity to help shift healthcare away from crisis management and toward proactive aging support. The Shenzhen clinic and stem cell platform represent an early but significant step in that direction.
